文献速递认知障碍与痴呆

基于淀粉样蛋白与tau PET时钟评估阿尔茨海默病血浆生物标志物变化时机

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
PubMed 文献 · Ann Neurol · 2025-06-20

本研究利用ADNI队列中784例纵向淀粉样蛋白PET和359例纵向tau PET数据,估算PET阳性年龄,并在190例和70例有纵向血浆标志物的个体中建模。结果显示除NfL外所有血浆标志物在PET阳性阈值前已异常,Aβ42/Aβ40早期异常后平台化,p-tau217、p-tau181、GFAP和NfL随疾病进展持续升高。

要点

  • 血浆Aβ42/Aβ40在淀粉样蛋白和tau PET时间线上均很早出现异常。
  • 血浆GFAP在tau PET时间线上早期异常,p-tau和NfL持续升高。
  • Aβ42/Aβ40或有助于识别极低淀粉样病理个体,p-tau、GFAP和NfL或有助于疾病分期。

核心结论

  • 血浆Aβ42/Aβ40可能有助于识别淀粉样病理水平极低的个体,而p-tau、GFAP和NfL可能有助于疾病进展分期。

研究设计与样本

  • 基于ADNI数据,纳入784例有纵向淀粉样蛋白PET和359例有纵向tau PET的个体,估算PET阳性年龄。
  • 190例有纵向血浆标志物及估算淀粉样蛋白PET阳性年龄,70例有纵向血浆标志物及估算tau PET阳性年龄。
  • 17例临床进展者中tau PET阳性年龄强烈预测症状发作年龄,并用于估算症状发作年龄。
  • 使用广义加性混合模型建模生物标志物轨迹,识别显著变化时间区间及超过预设异常阈值的最早时间点。

主要发现

  • 除NfL外,所有血浆生物标志物均在淀粉样蛋白和tau PET阳性的既定阈值之前出现异常。
  • 血浆Aβ42/Aβ40在淀粉样蛋白PET和tau PET时间线上均很早期出现异常。
  • 血浆GFAP在tau PET时间线上早期出现异常。
  • 血浆Aβ42/Aβ40水平平台化,而血浆p-tau217、p-tau181、GFAP和NfL水平在整个建模疾病进展中升高。
  • 不同生物标志物检测平台间这些变化时机存在一些差异。

关键数值与推荐

  • 血浆Aβ42/Aβ40、p-tau217、p-tau181、GFAP和NfL来自六个不同检测平台。
  • 淀粉样蛋白PET阳性年龄基于784例纵向淀粉样蛋白PET数据估算,tau PET阳性年龄基于359例纵向tau PET数据估算。
  • 纵向血浆生物标志物测量分别来自190例(淀粉样蛋白PET时间线)和70例(tau PET时间线)个体。
  • 症状发作年龄基于17例临床进展者中tau PET阳性年龄的强预测关系估算。

临床怎么用

  • 临床可考虑将血浆Aβ42/Aβ40用于识别淀粉样病理极低的个体。
  • p-tau、GFAP和NfL可用于辅助判断疾病进展阶段。
  • 解读血浆标志物时需注意不同检测平台间变化时机可能存在差异。

局限性

  • 纵向血浆生物标志物分析样本量有限(190例和70例)。
  • 症状发作年龄估算仅基于17例临床进展者。
  • 不同检测平台间变化时机存在差异,可能影响结果一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p-tau217, p-tau181, GFAP, and NfL) from six different assay platforms, alongside established AD biomarkers, using amyloid and tau positron emission tomography (PET)-based AD progression timelines. METHODS: Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), including 784 individuals with longitudinal amyloid PET and 359 with longitudinal tau PET, were analyzed to estimate the age at amyloid and tau PET positivity, respectively. Longitudinal plasma biomarker measurements were available from 190 individuals with an estimated amyloid PET positivity age and from 70 individuals with an estimated tau PET positivity age. In a subset of 17 clinical progressors, age at tau PET positivity strongly predicted symptom onset, allowing for estimation of symptom onset age. Biomarker trajectories based on time from amyloid or tau PET positivity or symptom onset were modelled using Generalized Additive Mixed models. Time intervals of significant biomarker change and the earliest timepoints at which biomarkers exceeded predefined abnormality thresholds were identified. RESULTS: All plasma biomarkers except NfL became abnormal prior to established thresholds for amyloid and tau PET positivity. Plasma Aβ42/Aβ40 became abnormal very early in both amyloid PET and tau PET timelines, while plasma GFAP became abnormal early in the tau PET timeline. Plasma Aβ42/Aβ40 levels plateaued, whereas plasma p-tau217, p-tau181, GFAP, and NfL levels increased throughout the modeled disease progression. Some variations in the timing of these changes were observed across different biomarker assays. INTERPRETATION: These findings suggest that the plasma Aβ42/Aβ40 may be useful in identifying individuals with very low levels of amyloid pathology, whereas p-tau, GFAP, and NfL may be useful in staging disease progression. ANN NEUROL 2025;98:508-523.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Milà-Alomà M, Tosun D, Schindler SE, et al. Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks. Ann Neurol. 2025. PMID: 40539416. doi:10.1002/ana.27285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。